A randomized controlled trial of mindfulness-based cognitive therapy for bipolar disorder
Article first published online: 9 DEC 2012
© 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd
Acta Psychiatrica Scandinavica
Volume 127, Issue 5, pages 333–343, May 2013
How to Cite
A randomized controlled trial of mindfulness-based cognitive therapy for bipolar disorder., , , , .
- Issue published online: 15 APR 2013
- Article first published online: 9 DEC 2012
- Manuscript Accepted: 1 OCT 2012
- National Health and Medical Research Council of Australia. Grant Numbers: 222708, 510135
- Rotary Australia
- mindfulness-based cognitive therapy;
- bipolar disorder;
- psychological treatment
To compare the efficacy of mindfulness-based cognitive therapy (MBCT) plus treatment as usual (TAU) to TAU alone for patients with bipolar disorder over a 12-month follow-up period.
Participants with a DSM-IV diagnosis of bipolar disorder were randomly allocated to either MBCT plus TAU or TAU alone. Primary outcome measures were time to recurrence of a DSM-IV major depressive, hypomanic or manic episode; the Montgomery-Åsberg Depression Rating Scale (MADRS); and Young Mania Rating Scale (YMRS). Secondary outcome measures were number of recurrences, the Depression Anxiety Stress Scales (DASS), and the State Trait Anxiety Inventory (STAI).
Ninety-five participants with bipolar disorder were recruited to the study (MBCT = 48; TAU = 47). Intention-to-treat (ITT) analysis found no significant differences between the groups on either time to first recurrence of a mood episode or total number of recurrences over the 12-month period. Furthermore, there were no significant between-group differences on the MADRS or YMRS scales. A significant between-group difference was found in STAI – state anxiety scores. There was a significant treatment by time interaction for the DAS – achievement subscale.
While MBCT did not lead to significant reductions in time to depressive or hypo/manic relapse, total number of episodes, or mood symptom severity at 12-month follow-up, there was some evidence for an effect on anxiety symptoms. This finding suggests a potential role of MBCT in reducing anxiety comorbid with bipolar disorder.